Stocktoria
Immunovant, Inc. IMVT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-14
Immunovant, Inc. financials (annual, from 10-K)
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| R&D expense | — | — | — | — | $101.8M |
| Income tax | $215,000 | $891,000 | $567,000 | $9,000 | -$84,000 |
| Net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M | -$156.7M |
| EPS (diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
| Operating cash flow | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M |
| Cash & equivalents | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M |
| Shareholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M |
Source: SEC EDGAR filings · CIK 0001764013 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.